Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025;25(2):75-85.
doi: 10.2174/0118715206301453240910044913.

Alterations of Krüppel-like Factor Signaling and Potential Targeted Therapy for Hepatocellular Carcinoma

Affiliations
Review

Alterations of Krüppel-like Factor Signaling and Potential Targeted Therapy for Hepatocellular Carcinoma

Rongfei Fang et al. Anticancer Agents Med Chem. 2025.

Abstract

Krüppel-like factors (KLFs, total 18 members) from the zinc finger protein (ZFP) super-family have a wide range of biological functions in hepatocellular carcinoma (HCC). This paper reviews the recent some progresses of aberrant KLFs with their potential values for diagnosis, prognosis, and targeted therapy in HCC. The recent advances of oncogenic KLFs in the diagnosis, prognosis, and targeted therapy of HCC were reviewed based on the related literature on PUBMED and clinical investigation. Based on the recent literature, KLFs, according to biological functions in HCC, are divided into 4 subgroups: promoting (KLF5, 7, 8, 13), inhibiting (KLF3, 4, 9~12, 14, 17), dual (KLF2, 6), and unknown functions (KLF1, 15, 16, or 18 ?). HCC-related KLFs regulate downstream gene transcription during hepatocyte malignant transformation, participating in cell proliferation, apoptosis, invasion, and metastasis. Some KLFs have diagnostic or prognostic value, and other KLFs with inhibiting promoting function or over-expressing inhibiting roles might be molecular targets for HCC therapy. These data have suggested that Abnormal expressions of KLFs were associated with HCC progression. Among them, some KLFs have revealed the clinical values of diagnosis or prognosis, and other KLFs with the biological functions of promotion or inhibition might be as effectively molecular targets for HCC therapy.

Keywords: Hepatocellular carcinoma; biomarker; diagnosis; krüppel-like factors; prognosis; regulatory mechanism; targeted therapy..

PubMed Disclaimer

Similar articles

References

    1. Huang D.Q.; Mathurin P.; Cortez-Pinto H.; Loomba R.; Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors. Nat Rev Gastroenterol Hepatol 2023,20(1),37-49 - DOI - PubMed
    1. Du Q.; Yuan J.; Ren Z.; Hepatocellular carcinoma patients with hepatitis B virus infection exhibited favorable survival from immune checkpoint inhibitors: A systematic review and meta-analysis. Liver Cancer 2024,13(4),344-354 - DOI - PubMed
    1. Shah P.A.; Patil R.; Harrison S.A.; NAFLD‐related hepatocellular carcinoma: The growing challenge. Hepatology 2022,77(1),323-338 - DOI - PubMed
    1. Ghazanfar H.; Javed N.; Qasim A.; Zacharia G.S.; Ghazanfar A.; Jyala A.; Shehi E.; Patel H.; Metabolic dysfunction-associated steatohepatitis and progression to hepatocellular carcinoma: A literature review. Cancers (Basel) 2024,16(6),1214 - DOI - PubMed
    1. Crane H.; Eslick G.D.; Gofton C.; Shaikh A.; Cholankeril G.; Cheah M.; Zhong J.H.; Svegliati-Baroni G.; Vitale A.; Kim B.K.; Ahn S.H.; Kim M.N.; Strasser S.I.; George J.; Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis. Clin Mol Hepatol 2024,30(3),436-448 - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources